OTCMKTS:INBP Integrated BioPharma (INBP) Stock Price, News & Analysis $0.29 0.00 (-0.83%) As of 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Integrated BioPharma Stock (OTCMKTS:INBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Integrated BioPharma alerts:Sign Up Key Stats Today's Range$0.29▼$0.2950-Day Range$0.26▼$0.3652-Week Range$0.16▼$0.42Volume1,000 shsAverage Volume20,863 shsMarket Capitalization$8.90 millionP/E Ratio7.18Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Read More Receive INBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Integrated BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address INBP Stock News HeadlinesINBP Integrated BioPharma, Inc.June 15, 2025 | seekingalpha.comIntegrated BioPharma Secures New Credit Line with PNCApril 21, 2025 | tipranks.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.July 30 at 2:00 AM | Porter & Company (Ad)Integrated Biopharma Inc (INBP)August 31, 2024 | investing.comIntegrated BioPharma, Inc. (INBP)July 19, 2024 | finance.yahoo.comIntegrated BioPharma Reports Results for its Quarter Ended December 31, 2023February 12, 2024 | finance.yahoo.comKBI Biopharma and Argonaut form drug manufacturing allianceJanuary 17, 2024 | msn.comKBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug ...January 16, 2024 | businesswire.comSee More Headlines INBP Stock Analysis - Frequently Asked Questions How have INBP shares performed this year? Integrated BioPharma's stock was trading at $0.3297 on January 1st, 2025. Since then, INBP stock has decreased by 12.9% and is now trading at $0.2872. How were Integrated BioPharma's earnings last quarter? Integrated BioPharma Inc. (OTCMKTS:INBP) issued its quarterly earnings data on Wednesday, May, 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $13.95 million for the quarter. Integrated BioPharma had a trailing twelve-month return on equity of 6.36% and a net margin of 2.37%. How do I buy shares of Integrated BioPharma? Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Integrated BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP). Company Calendar Last Earnings5/14/2025Today7/30/2025Next Earnings (Estimated)9/18/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:INBP CIK1016504 Webwww.integratedbiopharma.com Phone(973) 926-0816Fax973-926-1735Employees150Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.04 Trailing P/E Ratio7.24 Forward P/E RatioN/A P/E GrowthN/ANet Income$110 thousand Net Margins2.37% Pretax Margin3.55% Return on Equity6.36% Return on Assets4.84% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio1.70 Sales & Book Value Annual Sales$50.32 million Price / Sales0.18 Cash Flow$0.04 per share Price / Cash Flow6.51 Book Value$0.64 per share Price / Book0.45Miscellaneous Outstanding Shares30,980,000Free Float10,160,000Market Cap$8.97 million OptionableNot Optionable Beta0.81 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:INBP) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Integrated BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Integrated BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.